葛花枳椇子配伍对酒精性肝损伤大鼠肝脏功能及病理形态的影响

目的?探讨葛花枳椇子2∶1比例配伍后解酒保肝的作用，明确使用的最佳条件。方法?采用56°红星二锅头白酒灌胃建立酒精性肝损伤动物模型，并给予实验动物含生药量3、6、12?g/kg葛花枳椇子2∶1配伍药物，4、8、12周服药疗程，通过检测肝脏指数，谷氨酸转氨酶（ALT）、天门冬氨酸氨基转移酶(AST)、总蛋白(TP)、白蛋白(ALB)、碱性磷酸酶（ALP）等血清肝功能相关指标及肝脏病理形态，观察葛花、枳椇子2∶1比例配伍防治慢性酒精性肝损伤的作用。结果?葛花枳椇子配伍各剂量组给药4周对慢性酒精性肝损伤没有治疗作用。给药8周后配伍各剂量组的ALT均明显降低，与模型组相比有显著性差异（P<0.05~0.01）。给药12周后，配伍各剂量组AST明显下降，配伍低、高剂量组ALT下降，配伍低剂量组TP升高，配伍不同剂量组ALB升高，与模型组相比有显著性差异（P<0.05~0.01）；肝脏病理形态的变化也与肝功能指标相一致。结论?葛花枳椇子配伍各剂量组在给药8周和12周显示出一定解酒保肝作用，并随着治疗时间的延长，可以不同程度地改善相关指标，其中低剂量组较中、高剂量组效果好。 

Effects of Flos Puerariae-Semen Hoveniae Compatibility on Liver Function and Pathologic Morphology in Rats with Alcoholic Liver Disease

OBJECTIVE?To explore the de-alcoholic and hepatoprotective function of Flos puerariae-Semen hoveniae (2∶1) compatibility and determine the optimal dosage regimen. METHODS?Chronic alcoholic liver injury animal models were established by gavages of 56° Red Star Erguotou in rats. Experimental animals were given different doses (3， 6， 12?g/kg) of Flos puerariae-Semen hoveniae (2∶1) extracts within different medication courses (4， 8， 12 weeks). The liver index， ALT， AST， TP， ALB and ALP in serum were detected. The liver pathological morphologies were also observed. RESULTS?Chronic alcoholic liver injury models were successfully replicated. Flos puerariae-Semen hoveniae (2∶1) compatibility group of each dose displayed no therapeutic effect within four weeks. The level of ALT in Flos puerariae-Semen hoveniae (2∶1) compatibility group of each dose significantly decreased (P<0.05~0.01) after eight weeks administration. After 12 weeks， Flos puerariae-Semen hoveniae (2∶1) compatibility groups showed significantly decreased AST and increased ALB (P<0.05). Low and high dose groups displayed reduced ALT (P<0.05) while the low dose group showed increased TP (P<0.01). The changes in liver pathological morphology were fairly consistent with relevant indicators of liver function. CONCLUSION?Flos puerariae-Semen hoveniae (2∶1) compatibility group of each dose shows promising de-alcoholic and hepatoprotective effects after eight weeks of administration. The relevant indicators of liver function improve to varying degrees as the therapy time prolongs. Among them， low dose group performs better than medium and high dose groups.